Medicine
Rare Disease news, research, studies, and rapid health briefings. Visit Viral Vitalism for plain-language context, evidence boundaries, and related signals.
News cycle
Riaan Singh Digeorge received an experimental AAV9 gene therapy after a parent-led rare-disease development effort raised millions and reached an FDA-cleared IND.
Why now
A parent-led effort moved an ultra-rare disease from no approved treatment to first-in-human dosing, making the development story as important as the science.
Solid Biosciences reported a pediatric dosing milestone in the SGT-003 program, including a very young patient, alongside safety caveats and Phase 3 movement.
Why now
The update combines a powerful pediatric dosing milestone with a transition toward Phase 3, making it shareable only if the investigational boundary stays visible.
Sickle cell disease blocked Daniel Cressy's path to becoming a commercial pilot. New national coverage sharpened the human angle: he calls the post-Casgevy chapter his second life.
Why now
A patient-level milestone is moving gene therapy from approval news into real-world care in Louisiana and national coverage.
Regenxbio says FDA aligned on a path to resubmit Navsunli/RGX-121 for accelerated approval review, but the therapy is not approved.
Why now
FDA has reopened a filing path after the program's regulatory outlook had narrowed.
A new FDA draft guidance and recent reversals suggest the biggest bottleneck in gene therapy may no longer be the science alone. It may be the approval process itself.
Why now
Draft guidance and recent reversals suggest the rare-disease rulebook is changing in real time.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No miracle claims. Just better health signal.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
